Patents matching “formulation”

US 10675245

Sustained release formulation of a non-steroidal anti-inflammatory drug

Pacira Pharmaceuticals, Inc. · Granted Jun 9, 2020 · Expires Jun 4, 2040

US 10675325

Stable formulations of linaclotide

IRONWOOD PHARMACEUTICALS, INC. · Granted Jun 9, 2020 · Expires Jun 4, 2040

US 2020155578

Pharmaceutical Formulations for Subcutaneous Administration

ABBVIE INC [US] · Granted May 21, 2020 · Expires May 16, 2040

US 10653721

Peroxide formulations and methods and applicators for using the same

Aclaris Therapeutics, Inc. · Granted May 19, 2020 · Expires May 14, 2040

US 10653704

Inhalable formulation

Teva Branded Pharmaceutical Products R&D, Inc. · Granted May 19, 2020 · Expires May 14, 2040

US 10646523

Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions

AGAIN LIFE ITALIA SRL · Granted May 12, 2020 · Expires May 7, 2040

US 10646443

Sustained release olanzapine formulations

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted May 12, 2020 · Expires May 7, 2040

US 10646534

Formulation, preparation method and use of Chinese herbal medicine composition for soothing liver

INFINITUS (CHINA) COMPANY LTD. · Granted May 12, 2020 · Expires May 7, 2040

US 10646480

Formulations of pimavanserin

ACADIA Pharmaceuticals Inc. · Granted May 12, 2020 · Expires May 7, 2040

US 10646574

Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same

The Board of Regents of the University of Texas System · Granted May 12, 2020 · Expires May 7, 2040

US 10646485

Process of making stable abuse-deterrent oral formulations

Collegium Pharmaceutical, Inc. · Granted May 12, 2020 · Expires May 7, 2040

US 10639375

Progesterone formulations

Compass Therapeutics LLC · Granted May 5, 2020 · Expires Apr 30, 2040

US 10632072

Systems and methods for continuous manufacturing of liposomal drug formulations

UNIVERSITY OF CONNECTICUT · Granted Apr 28, 2020 · Expires Apr 23, 2040

US 10632173

Formulations and methods of use for alpha connexin C-terminal (ACT) peptides

FIRSTRING RESEARCH, INC. · Granted Apr 28, 2020 · Expires Apr 23, 2040

US 10632184

Compositions and methods for stabilizing alphaviruses with improved formulations

Takeda Vaccines, Inc. · Granted Apr 28, 2020 · Expires Apr 23, 2040

US 10624850

Emulsion formulations of an NK-1 receptor antagonist and uses thereof

Heron Therapeutics, Inc. · Granted Apr 21, 2020 · Expires Apr 16, 2040

US 10617642

Sustained release formulation of a non-steroidal anti-inflammatory drug

Pacira Pharmaceuticals, Inc. · Granted Apr 14, 2020 · Expires Apr 9, 2040

US 10610486

Sustained release formulation of a non-steroidal anti-inflammatory drug

Pacira Pharmaceuticals, Inc. · Granted Apr 7, 2020 · Expires Apr 2, 2040

US 10603326

Pharmaceutical formulation of 3α-ethynyl-3β-hydroxyandrostan-17-one oxime

Umecrine Cognition AB · Granted Mar 31, 2020 · Expires Mar 26, 2040

US 10588949

Factor IX polypeptide formulations

BIOVERATIV THERAPEUTICS INC. · Granted Mar 17, 2020 · Expires Mar 12, 2040

US 10589250

Automated purification and formulation device for radiopharmaceutical compounds

The Regents of the University of California · Granted Mar 17, 2020 · Expires Mar 12, 2040

US 10589997

Discrete carbon nanotubes with targeted oxidation levels and stable gel formulations thereof

MOLECULAR REBAR DESIGN, LLC · Granted Mar 17, 2020 · Expires Mar 12, 2040

US 10561744

Multi-encapsulated formulations made with oxidized cellulose

Covidien LP · Granted Feb 18, 2020 · Expires Feb 13, 2040

US 10561606

Injectable long-acting local anesthetic semi-solid gel formulations

MIRA PHARMA CORPORATION · Granted Feb 18, 2020 · Expires Feb 13, 2040